|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7803838||ALLERGAN||Compositions comprising nebivolol|| |
(2 years from now)
|US7838552||ALLERGAN||Compositions comprising nebivolol|| |
(4 years from now)
Byvalson is owned by Allergan.
Byvalson contains Nebivolol Hydrochloride; Valsartan.
Byvalson has a total of 2 drug patents out of which 0 drug patents have expired.
Byvalson was authorised for market use on 03 June, 2016.
Byvalson is available in tablet;oral dosage forms.
Byvalson can be used as method of treating hypertension.
The generics of Byvalson are possible to be released after 04 October, 2027.
Market Authorisation Date: 03 June, 2016
Treatment: Method of treating hypertension
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic